Jackson Creek Investment Advisors’s United Therapeutics UTHR Stock Holding History

Jackson Creek Investment Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,742	Closed	-$967K	–	381
2024 Q4	$967K	Buy	2,742 +114	+4%	+$41.9K	0.29%	172
2024 Q3	$942K	Sell	2,628 -418	-14%	-$141K	0.28%	175
2024 Q2	$970K	Sell	3,046 -517	-15%	-$137K	0.35%	160
2024 Q1	$818K	Buy	3,563 +457	+15%	+$103K	0.29%	199
2023 Q4	$683K	Buy	+3,106	New	+$716K	0.26%	202
2021 Q2	–	Sell	-1,846	Closed	-$309K	–	359
2021 Q1	$309K	Sell	1,846 -38	-2%	-$6.34K	0.11%	278
2020 Q4	$286K	Buy	+1,884	New	+$247K	0.11%	268

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jackson Creek Investment Advisors's UTHR Position: Q1 2025 in Review

Jackson Creek Investment Advisors sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 2,742 shares — an estimated $967K sold.

Jackson Creek Investment Advisors first reported a position in UTHR in Q4 2020 and held it in 7 quarters. The position peaked at $970K in Q2 2024. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

Jackson Creek Investment Advisors reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
Jackson Creek Investment Advisors sold 2,742 United Therapeutics shares in Q1 2025, an estimated $967K.
Jackson Creek Investment Advisors first reported a position in United Therapeutics in Q4 2020 and held it in 7 quarters.
Jackson Creek Investment Advisors's United Therapeutics position peaked at $970K in Q2 2024.
671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Jackson Creek Investment Advisors's 13F filing for Q1 2025, filed 5 May 2025.